Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection (KIRAL)

Fundacion SEIMC-GESIDA

Status: Completed

Conditions: HIV Infections

Study type: Observational

Funder types: Other

Identifiers

NCT03158077

GeSIDA 8715

Details and patient eligibility

About

Retrospective observational study, multicentric with Spanish hospitals, in which a switching or change strategy with RAL and ABC / 3TC guidelines was used, in the48 weeks before the start of the study, in order to determine parameters of Effectiveness and security.

Full description

The study consists of a 4-weeks data recording period, during which the follow-up information recorded by physicians in electronic or paper medical history will be analyzed from patients who opted for a change to that study pattern (RAL and ABC / 3TC).

Enrollment: 467 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient with chronic infection with HIV-1.
• Patients older than 18 years.
• Patients in ART in whom RAL + ABC / 3TC has been initiated in at least 48 Weeks prior to the start of the study.
• To have used the RAL + ABC / 3TC as a switching or change strategy
• HIV virological control (CV ≤ 50 copies / ml) for at least 24 weeks prior to initiation of study regimen

Exclusion criteria

• NAIVE patients who have started treatment with this regimen
• Absence of digital or physical records of visits made for consultation
• Patients who underwent treatment change within 48 weeks prior to study initiation

Trial design

467 participants in 1 patient group

Raltegravir + ABC/3TC

Description:

Switching or switching strategy with RAL and ABC / 3TC guidelines, 48 weeks before the start of the study